Potential therapeutic targeting of lncRNAs in cholesterol homeostasis

Wenchu Ye (yewenchu@gzhmu.edu.cn)  
Guangzhou Medical University  https://orcid.org/0000-0003-3007-9808

Shi-Feng Huang  
Guangzhou Medical College: Guangzhou Medical University

Lian-Jie Hou  
Guangzhou Medical College: Guangzhou Medical University

Hai-Jiao Long  
Central South University

Ting Jiang  
Guangzhou Medical College: Guangzhou Medical University

Kai Yin  
Guilin Medical University

Ching Yuan Hu  
University of Hawai‘i at Manoa

Guo-Jun Zhao  
Guangzhou Medical College: Guangzhou Medical University

Research Article

Keywords: Cholesterol homeostasis, LncRNAs, Liver disease, Lipid-related diseases

DOI: https://doi.org/10.21203/rs.3.rs-259158/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Maintaining cholesterol homeostasis is essential for normal cellular and systemic functions. Long non-coding RNAs (lncRNAs) represent a mechanism to fine-tune numerous biological processes by controlling gene expression. LncRNAs have emerged as important regulators in cholesterol homeostasis. Dysregulation of lncRNAs expression is associated with lipid-related diseases, suggesting that manipulating the lncRNAs expression could be a promising therapeutic approach to ameliorate liver disease progression and cardiovascular disease (CVD). However, given the high-abundant lncRNAs and the poor genetic conservation between species, much work is required to elucidate the specific role of lncRNAs in regulating cholesterol homeostasis. In this review, we highlighted the latest advances in the pivotal role and mechanism of lncRNAs in regulating cholesterol homeostasis. These findings provide novel insights into the underlying mechanisms of lncRNAs in lipid-related diseases and may offer potential therapeutic targets for treating lipid-related diseases.

1. Introduction

Cholesterol is a key organic molecule that exerts pleiotropic functions. Although its presence is crucial to the cell membranes’ permeability and fluidity, excessive cholesterol in the bloodstream can be harmful; therefore, maintaining cholesterol homeostasis is vital to normal cellular functioning. Cellular cholesterol maintains homeostasis by regulating cholesterol synthesis, cholesterol efflux, and cholesterol uptake from lipoprotein carriers[1, 2]. The aberrant trafficking and cellular cholesterol homeostasis usually lead to various diseases, including obesity, diabetes, cardiovascular disease, and cancer [2, 3]. Recent research has suggested that disrupted cholesterol homeostasis can also cause various congenital diseases (Table 1) [4, 5]. A growing body of evidence offers a close relationship between cholesterol homeostasis and acquired diseases, including cardiovascular disorders, liver diseases, and several types of cancer.

Long non-coding RNAs (lncRNAs), non-protein coding transcripts longer than 200 nucleotides (>200 bp) are important regulators of genome structure and gene expression. Recently, the contribution of lncRNAs in cholesterol homeostasis has just started to emerge [6, 7]. Numerous studies demonstrated that through various regulatory mechanisms, lncRNAs regulate cell development and cell type-specific expression patterns. LncRNAs influenced cholesterol homeostasis and the progression and development of lipid-related diseases, including liver and cardiovascular disease [8, 9]. With progress in next-generation sequencing technology, novel lncRNAs have been recognized and their diverse functions identified. However, the regulation by which many of the lncRNAs exhibit their functions is poorly understood. The low homology and conservation of lncRNAs across species pose a problem for developing lncRNA-based therapies. This review summarizes the latest insights on the roles of lncRNAs in cholesterol homeostasis and their potential implication for the treatment of lipid-related diseases.

2. LncRNAs Controlled Cholesterol Homeostasis
Numerous studies have found that lncRNAs have been characterized in many diseases, including fatty liver disease, hypertension, and cardiovascular disease, through disturbing cholesterol homeostasis (Table 2 and Figure 1). Moreover, several lncRNAs partook in the regulation of cholesterol homeostasis in the liver (Figure 2). Some lncRNAs played crucial roles in cholesterol homeostasis in macrophage cells (Figure 3). This review provides a comprehensive insight into the current knowledge regarding lncRNAs involved in regulating cholesterol homeostasis, which identifies potentially useful therapeutic targets for cholesterol modulation.

3. The Therapeutic Applications Of Lncrnas

LncRNAs have demonstrated promise as therapeutic targets mostly by preclinical studies and human studies. LncRNAs serve as biomarkers for the diagnosis, prognosis, and therapy of lipid-related diseases in humans. The characteristics of lncRNAs, including disease specificity, cell-type specificity, and relative ease in detection methods, make them suitable for patients with lipid-related diseases. Oligonucleotide therapeutics such as specific small interfering RNA technology, antisense oligonucleotides (ASOs), or small molecule inhibitors can also be used in treating a variety of diseases, including cancer, infectious diseases, atherosclerosis, liver, and kidney disease [10-12]. Companies such as RaNA Therapeutics Inc., Curna Inc., and MiNA Therapeutics Ltd. are making progress in developing lncRNAs-based strategies. However, the molecular mechanism by which lncRNAs work remains unclear, limiting their application as a therapeutic target. More studies are required before these lncRNAs can be placed in the therapeutic targets of lipid-related diseases. Here, we describe examples of current advances in each of the strategies mentioned above to target lncRNAs, as well as their potential therapeutic applications.

Regulation of cholesterol homeostasis by lncRNAs

In the last few years, evidence has been provided that lncRNAs play a key role in cholesterol accumulation, cholesterol efflux, cholesterol metabolism, and cholesterol biosynthesis, which have been implicated in lipid-related diseases, including liver disease (Figure 2) and cardiovascular disease (Figure 3) [13, 14]. Here, we have summarized our latest understanding of lncRNAs involved in cholesterol metabolism and potential targets for therapeutic applications

3.1 MIAT

The lncRNA myocardial infarction-associated transcript (MIAT), as a hypoxia-response gene, is located in chromosome 22q12.1 region. MIAT was markedly elevated in the serum of patients with symptoms of vulnerable atherosclerotic plaque [15]. MIAT increased the blood lipids levels, promoted atherosclerotic plaque formation, increased the lipid content, and decreased the collagen content of atherosclerotic plaques in apoE⁻/⁻ mice [16]. Silencing of MIAT attenuated atherosclerosis progression in an advanced atherosclerosis mouse model [15]. However, MIAT overexpression aggravated the atherosclerotic damage in apoE⁻/⁻ mice [16]. MIAT facilitated angiogenesis and the expression of inflammatory factors (IL-1β, IL-6, and TNF-a) by activating the PI3K/Akt pathway. MIAT was the target gene of N6-methyladenine (m6A) modification. m6A level was reduced with enlarged carotid plaque size and thickness in 207 patients with
atherosclerosis compared with 142 healthy people [17]. Ox-LDL-induced AlkB homolog 1 (ALKBH1) and m6A demethylation further promoted MIAT activity with the hypoxia-inducible factor 1α (HIF1α) motif (~1940/+166-Luc plasmids) but not with deletion [18]. Deficiency of ALKBH1 or HIF1α by siRNA transfection could strongly upregulate MIAT expression and the m6A levels in vitro [17]. Therefore, MIAT may provide a novel target for the treatment of atherosclerotic disease.

3.2 LINC00958

Long intergenic non-protein coding RNA 958 (LINC00958), a lipogenesis-related lncRNA, is located in chromosome 11p15.3 regions. LINC00958 was upregulated in hepatocellular carcinoma (HCC) tissues, especially in those with moderate/low differentiation, TNM III/IV stage, and microvascular invasion. Knockdown of LINC00958 in HCC cells decreased cellular cholesterol and triglyceride levels, whereas LINC00958 overexpression increased cholesterol and triglyceride levels [19]. METTL3-mediated m6A modification upregulated LINC00958 expression by stabilizing its RNA transcript and increased lipogenesis to promote HCC progression [19]. LINC00958 upregulated hepatoma-derived growth factor (HDGF) expression by sponged miR-3619-5p [19]. HDGF facilitated the expression of lipogenic genes, which promoted de novo lipogenesis and tumorigenesis. Thereby, LINC00958 augmented HCC lipogenesis and progression, implying that LINC00958 provided a novel perspective for targeted therapy of HCC.

3.3 H19

The H19 gene belongs to the H19-Igf2 locus, is located in an imprinted region of chromosome 11p15.5 near the insulin-like growth factor 2 (IGF2) gene in humans. Compared with the normal healthy people, the expression of H19 was higher in the blood of the patients with atherosclerosis [20], suggesting that H19 may be involved in atherosclerosis progression. In apoE−/− mice, overexpression of H19 aggravated atherosclerosis progression [21]; however, silencing of H19 protected against atherosclerosis [22]. Recently, H19 was reported to modulate hepatic metabolic homeostasis in non-alcoholic fatty liver disease (NAFLD). H19 promoted lipogenesis by directly inhibiting miR-130a expression in hepatocytes [23]. Meanwhile, miR-130a could inhibit lipid accumulation by directly down-regulating peroxisome proliferator-activated receptor γ (PPARγ) expression [23, 24]. Wang et al. illustrated that PPARγ promoted cholesterol efflux by regulating ABCA1 and ABCG1 in plaque in vivo and phagocytes in vitro, which could be blocked by PPARγ siRNA [24]. Overexpression of H19 in hepatocytes also promoted lipid accumulation and upregulated the expression of multiple genes involved in lipid synthesis, storage, and breakdown, while deficiency of H19 resulted in a decreased lipid accumulation in hepatocytes [25]. Therefore, H19 may become a new target for the therapy of lipid-related diseases, such as liver disease and cardiovascular disease.

3.4 GAS5

LncRNA growth arrest-specific 5 (GAS5), located on human chromosome 1q25.1, plays a crucial role in atherosclerosis’s pathogenesis. GAS5 was significantly increased in atherosclerosis patients’ plaque than
in normal people [26].

Overexpression of GAS5 increased lipid accumulation via inhibiting enhancer of zeste homolog 2 (EZH2)-mediated ABCA1 expression by histone methylation in THP-1 macrophage. In contrast, knockdown of GAS5 promoted reverse-transportation of cholesterol and inhibited lipid accumulation by upregulating the expression of ABCA1 [27]. GAS5 overexpression in apoE⁻/⁻ mice with atherosclerosis also increased total cholesterol (TC), free cholesterol (FC), cholesterol ester (CE), low-density lipoprotein (LDL) levels, aortic plaque, and lipid accumulation; however, silencing of GAS5 prevented the progression of atherosclerosis [27]. Previous studies have shown that GAS5 silencing repressed atherosclerosis's malignant progression [28]. Thus, targeting GAS5 might be a promising way for therapy for atherosclerosis.

3.5 CHROME

Cholesterol induced regulator of metabolism RNA (CHROME), also known as PRKRA-AS1, is located in a locus on human chromosome 2q31.2, regulates cellular and systemic cholesterol homeostasis. Analysis of blood and tissue samples from healthy individuals and coronary artery disease (CAD) patients revealed that CHROME is upregulated in the plasma and atherosclerotic plaques of patients with atherosclerotic disease [29]. Using gain- and loss-of-function approaches, CHROME promoted cholesterol efflux and HDL biogenesis in the liver and macrophages via inhibiting the actions of functionally related miRNAs, such as miR-27b, miR-33a/b, and miR-128. Conversely, CHROME knockdown inhibited ABCA1 expression in human hepatocytes and macrophages, which blocks cholesterol efflux and the formation of nascent high-density lipoprotein (HDL) [29]. Therefore, CHROME may be a clinical biomarker for treating cholesterol-related diseases.

3.6 MEG3

Maternally expressed gene 3 (MEG3) is a lncRNA located in a locus on chromosome 14q32.2 thought to be associated with human lipid metabolic disorders. A study recently demonstrated that the expression of MEG3 was reduced in serum samples from patients with atherosclerosis [30]. MEG3 deficiency remarkably abolished hepatic TG accumulation in HFD mice and ob/ob mice [31, 32]. MEG3 alleviated NAFLD after high-content hydrogen water treatment in a mouse model [31]. MEG3 expression is negatively correlated with lipogenesis-related genes, including sterol regulatory element-binding protein-1 (SREBP-1), LXRα, Carbohydrate response element-binding protein (ChREBP), Stearyl-coenzyme A desaturase 1 (SCD1), acetyl-CoA carboxylase 1 (ACC1), and fatty acid synthase (FAS), in NAFLD mice [33]. Overexpression of MEG3 significantly inhibited the expression levels of lipogenesis-related genes and lowered FFA-induced lipid accumulation in HepG2 cells. Bioinformatic analysis and mechanistic studies illustrated that MEG3 competitively bound to the miR-21 with LRP6, followed by the inhibition of the mTOR pathway and inhibited hepatic lipogenesis [33]. Therefore, the targeted suppression of MEG3 may serve as a potential therapy for lipid-related diseases.

3.7 LeXis
LeXis is a lipid-responsive IncRNA, highly expressed in the hepatic tissue, and robustly induced by Western diet (high in fat and cholesterol) and pharmacologic liver X receptors (LXRs) activation [34]. Hepatic overexpression of LeXis in mice decreased plasma cholesterol, whereas LeXis knockout mice had the opposite phenotype of increased serum cholesterol level and upregulated cholesterol biosynthetic gene expression [35]. Raising or lowering LeXis levels in the liver and plasma affected cholesterol biosynthesis and altered the cholesterol levels by LXRs activation. LXRs are transcriptional regulators of cholesterol homeostasis. Under conditions of excess cholesterol, LXR activation-induced apoE, ABCA1, and ABCG1 expression, which involved in cholesterol efflux, facilitated cholesterol esterification and inhibited cholesterol uptake [34, 36]. Overexpression of LXRs significantly promoted cholesterol efflux via the upregulation of ABCA1 and ABCG1 [37]; conversely, shRNA-mediated knockdown suppressed ABCA1 and ABCG1 expression and promoted intracellular cholesterol accumulation [38]. Taken together, LeXis has important implications in developing novel therapeutic strategies for treating lipid-related diseases.

3.8 CDKN2B-AS1

CDKN2B-AS1, also known as ANRIL, is located within the CDKN2B-CDKN2A gene cluster at chromosome 9p21 in humans. Prior studies have demonstrated that it was expressed significantly higher in hypertension patients than in healthy controls and was particularly associated with cardiovascular disease [39]. Transcript variants of CDKN2B-AS1 have also been shown to play important regulatory roles in various diseases, including malignant tumors, atherosclerosis, hypertension, and diabetes [10, 40-42]. CDKN2B-AS1 promoted cholesterol efflux by inhibiting A disintegrin and metalloprotease 10 (ADAM10) expression in atherosclerosis [43]. Overexpression of ADAM10 facilitated the intracellular accumulation of cholesterol, while knockdown of ADAM10 promoted cholesterol efflux. Hence, CDKN2B-AS1 may serve as a biomarker for atherosclerosis.

3.9 LASER

A novel IncRNA, lipid Associated Single nucleotide polymorphism gEne Region (LASER), is located near SNP rs486394 in chromosome 11q12 region. Clinical studies previously revealed that LASER expression is positively associated with cholesterol levels. LASER is highly expressed in both hepatocytes and peripheral mononuclear cells (PBMCs). siRNAs mediated knockdown of LASER improved intracellular cholesterol levels and affected the expression of cholesterol metabolism genes at both protein and mRNA levels by inhibiting proprotein convertase subtilisin/kexin 9 (PCSK9) expression [44]. PCSK9, a major determinant of cholesterol homeostasis, is mainly secreted from the liver and enhances circulating low-density lipoprotein cholesterol (LDL-C) concentrations in circulating blood [45]. Thus, targeting LASER therapy may be a practical approach to ameliorate cholesterol levels in clinics.

3.10 HOXC-AS1

LncRNA HOXC cluster antisense RNA 1 (HOXC-AS1) is located in chromosome 12q13.13 regions and has two exons. By performing microarray analysis and RT-PCR, the expression levels of HOXC-AS1 and homeobox C6 (HOXC6) were both downregulated in human atherosclerotic plaques when compared to
normal intima tissues [46]. Lentivirus-mediated overexpression of HOXC-AS1 suppressed ox-LDL-induced cholesterol accumulation by promoting HOXC6 expression in THP-1 macrophages [46]. Numerous studies have reported that HOX gene networks are involved in human adipogenesis, particularly HOXC6 inhibited intracellular lipid accumulation [47]. Thus, HOXC-AS1 could be a promising therapeutic target in preventing atherosclerosis.

3.11 LncARSR

LncRNA regulator of Akt signaling associated with HCC and RCC (LncARSR) is located in chromosome 9q21.31 regions. The expression levels of LncARSR were increased both in patients with hypercholesterolemia and high-cholesterol diet fed mice [48]. Adenoviruses-mediated overexpression of LncARSR in mice contributed to elevated lipid levels in both serum and liver fragments. However, knockdown of LncARSR in mice fed with a high cholesterol diet exhibited a marked reduction in plasma lipid levels than control mice [48]. Moreover, LncARSR overexpression facilitated HMG-CoA reductase (HMGR) expression and the rate-limiting enzyme of cholesterol synthesis, accompanied by the augment of hepatic de novo cholesterol synthesis rate. Mechanistically, LncARSR promoted the expression of SREBP-2, which regulated the expression of cholesterol-related genes, such as HMGR and LDLR [49]. Hence, LncARSR promoted hepatic cholesterol biosynthesis and implied that LncARSR might serve as a therapeutic target for cholesterol homeostasis disorder.

3.12 ENST00000602558.1

ENST00000602558.1 is located on a CAD, triglyceride (TG), and HDL susceptibility region (chr12q24.31) [50, 51]. Li et al. performed a transcriptome-wide overview of aberrantly expressed lncRNAs in CAD patients, ENST0000444488.1 was identified as a novel lncRNA biomarker for diagnosing CAD [52]. Overexpression of ENST0000602558.1 downregulated ABCG1 expression and exacerbated lipid accumulation in VSMCs, while knockdown of ENST0000602558.1 upregulated ABCG1 expression and decreased lipid accumulation [53]. Thus, ENST0000602558.1 may be a novel biomarker for diagnosing atherosclerosis.

3.13 LOC286367

LOC286367 is located in the chromosome 9q31.1 region. By performing bioinformatic analysis of lncRNAs and mRNA differentially expressed in THP-1 macrophages, Ma et al. proposed that LOC286367 and ABCA1 were located on the same chromosome with opposite transcription directions [54]. Overexpression of LOC286367 inhibited ABCA1 expression, which resulted in the intracellular lipid accumulation [54]. ABCA1 overexpression in C57BL/6 mice resulted in an anti-atherogenic profile with reduced plasma cholesterol, free cholesterol, cholesteryl ester, and non-high-density lipoprotein cholesterol (HDL-C) levels, but with increased HDL-C, apoA-I, and apoE levels [55]. However, ABCA1 knockout mice displayed increased atherosclerosis compared to control mice [56]. Hence, targeting LOC286367 might bring significant benefits to the clinical outcome of atherosclerotic cardiovascular diseases.
3.14 RP5-833A20.1

RP5-833A20.1 is located in intron 2 of the nuclear factor IA (NFIA) gene. RP5-833A20.1 expression was upregulated, whereas NFIA expression was downregulated in human acute monocytic leukemia macrophage-derived foam cells using microarray analysis [57]. RP5-833A20.1 regulated cholesterol homeostasis by NFIA. Lentivirus-mediated NFIA overexpression increased HDL-C circulation, decreased LDL-C cholesterol, and very-low-density lipoprotein cholesterol (VLDL-C) circulation [57], which resulted in the regression of atherosclerosis in apoE-/ mice. Thus, RP5-833A20.1 may represent a therapeutic target to ameliorate lipid-related diseases.

4. Therapeutic Use Of Lncrnas In Diseases

During the last decades, developments in genome-wide analyses have confirmed that almost all human genomes are transcribed with IncRNAs. Many IncRNAs have been known to be functional in mammals and are involved in various physiological and pathophysiological processes by epigenetics and transcriptional or post-transcriptional regulatory mechanisms [58, 59]. Recently, many studies have demonstrated that IncRNAs are involved in the pathophysiology of various pathological conditions, including cancers [60], autoimmune diseases [61], and neurological disorders [62] and cardiovascular diseases [63].

Previous studies have demonstrated novel IncRNA biomarkers and identify therapeutic IncRNA targets [64, 65]. A novel Inc030 was highly expressed in breast cancer [66]. Inhibition of Inc030 expression by lentivirus-mediated short hairpins RNAs (shRNAs) reported markedly impaired colony formation and inhibited breast cancer initiation and progression, whereas ectopic Inc030 overexpression significantly increased colony formation and promoted initiation and progression of breast cancer [66]. These results demonstrated that Inc030 could act as a therapeutic target and biomarker in breast cancer. Similarly, IncRNA PVT1 was verified to function as a tumor promoter in gastric cancer. It is reported that PVT1 was highly expressed in gastric cancer (GC) tissues, and high PVT1 level was correlated with tumor stage, lymph node metastasis, and poor prognosis [67]. Overexpression of PVT1 greatly promoted the GC cell epithelial-to-mesenchymal transition (EMT) process and tumor metastasis in vitro and in vivo [67]. These findings indicated that PVT1 has an important implication for future therapy of the GC. A similar vector has already been demonstrated as effective in animal studies for thyroid cancer therapy [68]. Other circulating IncRNAs also have been verified as biomarkers in the diagnosis and prognosis of many diseases. For example, prostate-specific IncRNA prostate cancer antigen 3 (PCA3) levels have been suggested as a diagnostic biomarker of prostate cancer [69]. Other IncRNAs used as biomarkers include circulating plasma H19 for gastric cancer [70], HULC in hepatocellular carcinoma [71], circulating IncRNA SNHG11 colorectal cancer[72], circulating exosomal IncRNA-GC1 in gastric cancer[73], and HOTAIR in various cancers including breast, colorectal, liver, gastric, lung, and thyroid [74-78].

Other than cancers, IncRNAs also have been investigated as promising biomarkers for atherosclerotic disease [79]. CoroMarker was highly expression in circulating peripheral blood monocytes (PBMCs) and
plasma from patients with coronary artery disease (CAD) [80]. CoroMarker acts as a candidate biomarker for CAD with an AUC of 0.920 and a 95% confidence interval of 0.892-0.947, and it could successfully distinguish CAD out of patients [80]. CoroMarker is stable, sensitive, and mainly in the extracellular vesicle, probably from monocytes [81]. LIPCAR has been identified from the plasma RNA from patients with myocardial infarction [82]. LIPCAR is consistently detectable in the plasma and is significantly increased in patients with myocardial infarction during later stages and ischemic and non-ischemic heart failure. Importantly, higher LIPCAR levels identified patients developing cardiac remodeling and were also reported to be an independent biomarker of future cardiovascular deaths [82]. Another study compared the expression of IncRNAs in the peripheral blood cells between healthy and myocardial infarction patients. It demonstrated that cardiac hypertrophy-associated transcript (CHAST), MALAT1 were significantly upregulated in myocardial infarction patients [83-85]. These findings provided a promising therapeutic strategy for acquiring atherosclerotic diseases and shed light on the clinical implication of IncRNA-associated ceRNA mechanisms in atherosclerotic disease deterioration.

5. Conclusions And Future Directions

The importance of cholesterol homeostasis function is underscored by the diverse regulatory pathways that maintain cellular cholesterol levels within a narrow range. Cellular cholesterol deficiency and accumulation, hallmarks of some lipid-related diseases involving the liver and angiogenesis, highlight the importance of maintaining cholesterol homeostasis in various cell lines. In humans, cholesterol homeostasis is maintained by multiple feedback and compensatory mechanisms. LncRNAs have been involved in regulating cholesterol homeostasis, and several studies focused on IncRNAs regulated by cholesterol. These IncRNAs function not only in normal metabolism and cholesterol homeostasis but also in the progression of lipid-related diseases. In this review, the discovery of IncRNAs has provided novel and sensitive biomarkers and therapeutic targets for patients with lipid-related diseases. Dysregulation in IncRNA expression could also be a cause of lipid-related diseases. Further, a lack of specific, secure, and effective delivery systems limits IncRNAs' use in treating lipid-related diseases. Future studies should focus on tissue-specific interference or overexpression of IncRNAs to achieve the targeted therapy of patients with lipid-related diseases.

Most IncRNAs frequently display tissue and disease-specific expression patterns and less conserved than protein-coding genes [86]. Due to unique features, IncRNAs may be superior therapeutic targets than existing protein-coding genes for various disease diagnosis and prognosis. Additionally, IncRNAs act as a biologically functional molecule, and their expression may be better biomarker candidates for various disease states [87]. However, the function of most IncRNAs is still unknown, their role in physiology, development, and disease. Their effective use as therapeutic targets requires an enormous number of studies. Investigations are required to check the pharmacokinetics and toxicity of IncRNAs. It is also important to further explore these regulatory RNAs' novel biologic characteristics and provide potential novel treatment options. However, IncRNA holds great therapeutic promise for potential intervention. Because of its tissue and disease-specific expression, IncRNA has great therapeutic interventions as a biomarker and an important therapeutic target for treating diseases. Considerable research is currently
investigating the biological function of these IncRNAs for diagnostic, prognostic, and therapeutic. In this field, the research is increasing exponentially over the next decade will teach us more about the diagnostic, prognostic, and therapeutic of these IncRNAs.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and material
Not applicable.

Competing interests
The authors declare no conflict of interest.

Funding
The authors gratefully acknowledge the financial support from the National Natural Sciences Foundation of China (81870337 and 82000407) and the Guangdong Natural Sciences Foundation (2019A1515110080).

Authors' contributions
Guo-Jun Zhao, Ching Yuan Hu, and Wen-Chu Ye designed and outlined the article. Wen-Chu Ye, Lian-Jie Hou, Guo-Jun Zhao, and Ching Yuan Hu conducted the literature article. Wen-Chu Ye, Shi-Feng Huang, Ting Jiang, and Hai-Jiao Long analyzed the literature and provided suggestions. Wen-Chu Ye, Shi-Feng Huang, and Lian-Jie Hou provided ideas and wrote the article. All the authors have approved the manuscript for submission.

Acknowledgements
None.

References
1. L. Goldstein, M.S. Brown. Regulation of the mevalonate pathway. Nature. 1990; 343(6257): 425-430.
2. Y. Wang, P. Liu, J. Weng, E. Sontag, R.G. Anderson. A cholesterol-regulated PP2A/HePTP complex with dual specificity ERK1/2 phosphatase activity, EMBO J. 2003; 22(11): 2658-2667.
3. Li, H. Gu, D. Zhang, ATP-binding cassette transporters and cholesterol translocation. IUBMB life. 2013; 65(6): 505-512.

4. Rottiers, S.H. Najafi-Shoushtari, F. Kristo, S. Gurumurthy, L. Zhong, Y. Li, et al. MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol. 2011; 76: 225-233.

5. Defesche, S. Gidding, M. Harada-Shiba, R. Hegele, R. Santos, A. Wierzbicki. Familial hypercholesterolaemia. Nat Rev Dis Primers. 2017; 3:17093.

6. K. Singh, B. Aryal, X. Zhang, Y. Fan, N.L. Price, et al. Posttranscriptional regulation of lipid metabolism by non-coding RNAs and RNA binding proteins. Semin Cell Dev Biol. 2018; 81:129-140.

7. Liu, L. Zheng, Q. Wang, Y.W. Hu. Emerging roles and mechanisms of long noncoding RNAs in atherosclerosis. Int J Cardiol. 2017; 228: 570-582.

8. Ou, X. Li, S. Zhao, S. Cui, J. Tu. Long non-coding RNA CDKN2B-AS1 contributes to atherosclerotic plaque formation by forming RNA-DNA triplex in the CDKN2B promoter. EBioMedicine. 2020; 55: 102694.

9. Han, S. Huang, P. Xue, J. Fu, L. Liu, C. Zhang, et al. PTPRE-AS1LncRNA modulates M2 macrophage activation and inflammatory diseases by epigenetic promotion of PTPRE. Sci Adv. 2019; 5(12): eaax9230.

10. M. Haag, M.F. Gulen, L. Reymond, A. Gibelin, L. Abrami, A. Decout, et al. Targeting STING with covalent small-molecule inhibitors. Nature. 2018; 559(7713): 269-273.

11. Bernardo, J. Ooi, R. Lin, J. McMullen. miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. Future Med Chem. 2015; 7(13): 1771-1792.

12. Gong, X. Teng, J. Li, X. Liang. Antisense Oligonucleotide-Conjugated Nanostructure-Targeting IncRNA MALAT1 Inhibits Cancer Metastasis. ACS Appl Mater Interfaces. 2019: 11(1):37-42.

13. Zeng, K. Ren, X. Zhu, Z. Zheng, G. Yi. Long Noncoding RNAs: Advances in Lipid Metabolism. Adv Clin Chem. 2018; 87:1-36.

14. Chen. Progress and prospects of long noncoding RNAs in lipid homeostasis. Mol Metab.2016; 5(3):164-170.

15. Ye, S. Yang, Y. Xia, R. Hu, S. Chen, B. Li, et al. LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation. Cell Death Dis.2019; 10(2):138.

16. Sun, Y. Li, Z. Ji. Up-regulation of MIAT aggravates the atherosclerotic damage in atherosclerosis mice through the activation of PI3K/Akt signaling pathway. Drug Deliv.2019; 26(1): 641-649.

17. Wu, Y. Pei, Y. Zhu, M. Jiang, C. Wang, W. Cui, et al. Association of N-methyladenine DNA with plaque progression in atherosclerosis via myocardial infarction-associated transcripts. Cell Death Dis.2019; 10(12): 909.

18. Li, Y. Zhang, Y. Guo, R. Liu, Q. Yu, L. Gong, et al. ALKBH1 promotes lung cancer by regulating m6A RNA demethylation. Biochem Pharmacol. 2020;114284.
19. Zuo, Z. Chen, W. Gao, Y. Zhang, J. Wang, J. Wang, et al. M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020; 13(1): 5.

20. X. Pan. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci. 2017; 21(2): 322-328.

21. Huang, L. Wang, Y. Mao, G. Nan. Long Noncoding RNA-H19 Contributes to Atherosclerosis and Induces Ischemic Stroke via the Upregulation of Acid Phosphatase 5. Front Neurol. 2019;10: 32.

22. Yang, F. Tang, F. Wei, L. Yang, C. Kuang, H. Zhang, et al. Silencing of long non-coding RNA H19 downregulates CTCF to protect against atherosclerosis by upregulating PKD1 expression in ApoE knockout mice. Aging.2019; 11(22): 10016-10030.

23. Liu, T. Tang, G. Wang, B. Liu. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease. Biosci Rep.2019; 39(7).

24. Wang, Y. Yang, X. Sun, F. Tian, S. Guo, W. Wang, et al. Sonodynamic therapy-induced foam cells apoptosis activates the phagocytic PPARγ-LXRA-ABCA1/ABCG1 pathway and promotes cholesterol efflux in advanced plaque. Theranostics. 2018; 8(18): 4969-4984.

25. Wang, Y. Cao, L. Shu, Y. Zhu, Q. Peng, L. Ran, et al. Long non-coding RNA (lncRNA) H19 induces hepatic steatosis through activating MLXIPL and mTORC1 networks in hepatocytes. J Cell Mol Med.2020; 24(2):1399-1412.

26. Chen, H. Yao, J. Hui, S. Ding, Y. Fan, Y. Pan, et al. Global transcriptomic study of atherosclerosis development in rats. Gene.2016; 592(1): 43-48.

27. Meng, H. Yao, L. Wang, M. Yu, S. Shi, Z. Yuan, et al. Knockdown of GAS5 Inhibits Atherosclerosis Progression via Reducing EZH2-Mediated ABCA1 Transcription in ApoE Mice. Mol Ther Nucleic Acids.2020; 19: 84-96.

28. Shen, X. Zheng, Z. Zhu, S. Zhao, Q. Zhou, Z. Song, et al. Silencing of GAS5 represses the malignant progression of atherosclerosis through upregulation of miR-135a. Biomed Pharmacother.2019; 118: 109302.

29. Hennessy, C. van Solingen, K. Scacalossi, M. Ouimet, M. Afonso, J. Prins, et al. The long noncoding RNA CHROME regulates cholesterol homeostasis in primate. Nat Metab. 2019; 1(1): 98-110.

30. Liu, L. Jia, D. Min, Y. Xu, J. Zhu, Z. Sun. Baicalin inhibits proliferation and promotes apoptosis of vascular smooth muscle cells by regulating the MEG3/p53 pathway following treatment with ox-LDL. Int J Mol Med. 2019; 43(2): 901-913.

31. Wang, J. Wang. High-content hydrogen water-induced downregulation of miR-136 alleviates non-alcoholic fatty liver disease by regulating Nrf2 via targeting MEG3. Biol Chem. 2018; 399(4): 397-406.

32. Zhu, H. Li, Y. Wu, J. Zhou, G. Yang, W. Wang. IncRNA MEG3 promotes hepatic insulin resistance by serving as a competing endogenous RNA of miR-214 to regulate ATF4 expression. Int J Mol Med. 2019; 43(1): 345-357.

33. Huang, F. Huang, H. Liu, T. Zhang, M. Yang, C. Sun. LncRNA MEG3 functions as a ceRNA in regulating hepatic lipogenesis by competitively binding to miR-21 with LRP6. Metabolism. 2019; 94:
1-8.

34. Sallam, M. Jones, T. Gilliland, L. Zhang, X. Wu, A. Eskin, et al. Feedback modulation of cholesterol metabolism by the lipid-responsive non-coding RNA LeXis. Nature. 2016; 534(7605): 124-128.

35. Ha, A. Van Camp, R. Bauer. Genetics-driven discovery of novel regulators of lipid metabolism. Curr Opin Lipidol. 2019; 30(3): 157-164.

36. Zhao, J. Wu, S. Liangpunsakul, L. Wang. Long Non-coding RNA in Liver Metabolism and Disease: Current Status. Liver Res. 2017; 1(3): 163-167.

37. Ceroi, D. Masson, A. Roggy, C. Roumier, C. Chagué, T. Gauthier, et al. LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis. Blood. 2016; 128(23): 2694-2707.

38. Nakaya, M. Ayaori, T. Hisada, S. Sawada, N. Tanaka, N. Iwamoto, et al. Telmisartan enhances cholesterol efflux from THP-1 macrophages by activating PPARgamma. J Atheroscler Thromb. 2007; 14(3): 133-41.

39. Bayoglu, H. Yuksel, H. Cakmak, A. Dirican, M. Cengiz. Polymorphisms in the long non-coding RNA CDKN2B-AS1 may contribute to higher systolic blood pressure levels in hypertensive patients. Clin Biochem. 2016; 49(10-11): 821-827.

40. Huang, B. Xiang, Y. Liu, Y. Wang, H. Kan. LncRNA CDKN2B-AS1 promotes tumor growth and metastasis of human hepatocellular carcinoma by targeting let-7c-5p/NAP1L1 axis. Cancer Lett. 2018; 437: 56-66.

41. Restrepo, S. Laper, E. Farber-Eger, D. Crawford. Local genetic ancestry in CDKN2B-AS1 is associated with primary open-angle glaucoma in an African American cohort extracted from de-identified electronic health records. BMC Med Genomics. 2018; 11: 70.

42. Hubberten, G. Bochenek, H. Chen, R. Häsl er, R. Wiehe, P. Rosenstiel, et al. Linear isoforms of the long noncoding RNA CDKN2B-AS1 regulate the c-myc-enhancer binding factor RBMS1. Eur J Hum Genet. 2019; 27(1): 80-89.

43. Li, S. Han, Q. Sun, Y. Yao, S. Li, C. Yuan, et al. Long non-coding RNA CDKN2B-AS1 reduces inflammatory response and promotes cholesterol efflux in atherosclerosis by inhibiting ADAM10 expression. Aging. 2019; 11(6): 1695-1715.

44. Li, Z. Hu, W. Zhang, J. Yu, Y. Yang, Z. Xu, et al. Regulation of Cholesterol Homeostasis by a Novel Long Non-coding RNA LASER. Sci Rep. 2019; 9(1): 7693.

45. Seidah, Z. Awan, M. Chrétien, M. Mbikay. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014; 114(6): 1022-1036.

46. Huang, Y. Hu, J. Zhao, X. Ma, Y. Zhang, F. Guo, et al. Long Noncoding RNA HOXC-AS1 Suppresses Ox-LDL-Induced Cholesterol Accumulation Through Promoting HOXC6 Expression in THP-1 Macrophages. DNA Cell Biol. 2016; 35(11): 722-729.

47. Gao, Y. Wang, X. Chen, Y. Peng, F. Chen, Y. He, et al. MiR-127 attenuates adipogenesis by targeting MAPK4 and HOXC6 in porcine adipocytes. J Cell Physiol. 2019; 234(12): 21838-21850.
48. Huang, S. Chen, D. Cai, D. Bian, F. Wang. Long noncoding RNA IncARSIR promotes hepatic cholesterol biosynthesis via modulating Akt/SREBP-2/HMGCR pathway. Life Sci. 2018; 203: 48-53.

49. Cirera-Salinas, M. Pauta, R. Allen, A. Salerno, C. Ramírez, A. Chamorro-Jorganes, et al. Mir-33 regulates cell proliferation and cell cycle progression. Cell cycle. 2012; 11(5): 922-933.

50. Zhao, A. Rasheed, E. Tikkanen, J. Lee, A. Butterworth, J. Howson, et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. Nat Genet. 2017; 49(10): 1450-1457.

51. Klarin, Q. Zhu, C. Emdin, M. Chaffin, S. Homer, B. McMillan, et al. Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nat Genet. 2017; 49(9): 1392-1397.

52. Li, L. Wang, H. Li, X. Han, S. Chen, B. Yang, et al. Characterization of LncRNA expression profile and identification of novel LncRNA biomarkers to diagnose coronary artery disease. Atherosclerosis. 2018; 275: 359-367.

53. Cai, H. Zhu, X. Ning, L. Li, B. Yang, S. Chen, et al. LncRNA ENST00000602558.1 regulates ABCG1 expression and cholesterol efflux from vascular smooth muscle cells through a p65-dependent pathway. Atherosclerosis. 2019; 285: 31-39.

54. Ma, T. Wang, Z. Zhao, Y. Jiang, S. Ye. Propofol Suppresses Proinflammatory Cytokine Production by Increasing ABCA1 Expression via Mediation by the Long Noncoding RNA LOC286367. Mediators Inflamm. 2018; 2018: 8907143.

55. Joyce, M. Amar, G. Lambert, B. Vaisman, B. Paigen, J. Najib-Fruchart, et al. The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice. Proc Natl Acad Sci U S A. 2002; 99(1): 407-412.

56. Gao, L. He, X. Yu, Z. Zhao, G. Wang, J. Zou, et al. CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-catenin/TCF21 pathway. J Lipid Res. 2019; 60(12): 2020-2033.

57. Hu, J. Zhao, S. Li, J. Huang, Y. Qiu, X. Ma, et al. RP5-833A20.1/miR-382-5p/NFIA-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis and inflammatory reaction. Arterioscler Thromb Vasc Biol. 2015; 35(1): 87-101.

58. Correia de Sousa, M. Gjorgjieva, D. Dolicka, C. Sobolewski, M. Foti. Deciphering miRNAs’ Action through miRNA Editing. Int J Mol Sci. 2019; 20(24).

59. Zhang, M. Hamblin, K. Yin. The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 2017; 14(12): 1705-1714.

60. Bhan, M. Soleimani, S. Mandal. Long Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 2017; 77(15); 3965-3981.

61. Lodde, G. Murgia, E. Simula, M. Steri, M. Floris, M. Idda. Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases. Biomolecules. 2020; 10(7).

62. Wu, J. Bono, Y. Tao. Long noncoding RNA (lncRNA): a target in neuropathic pain. Expert Opin Ther Targets. 2019; 23(1): 15-20.
63. Uchida, S. Dimmeler. Long noncoding RNAs in cardiovascular diseases. Circ Res. 2015; 116(4): 737-750.

64. Zhang, S. Sun, J. Pu, A. Tsang, D. Lee, V. Man, et al. Long non-coding RNA expression profiles predict clinical phenotypes in glioma. Neurobiol Dis. 2012; 48(1): 1-8.

65. Yu, Q. Xu, F. Liu, X. Ye, J. Wang, X. Meng. Identification and validation of long noncoding RNA biomarkers in human non-small-cell lung carcinomas. J Thorac Oncol.2015; 10(4): 645-654.

66. Qin, Y. Hou, S. Liu, P. Zhu, X. Wan, M. Zhao, et al. A Novel Long Non-Coding RNA Inc030 Maintains Breast Cancer Stem Cell Stemness by Stabilizing SQLE mRNA and Increasing Cholesterol Synthesis. Adv Sci (Weinh). 2021; 8(2):2002232.

67. Wang, B. Xiao, T. Yu, L. Gong, Y. Wang, X. Zhang, et al. IncRNA PVT1 promotes the migration of gastric cancer by functioning as ceRNA of miR-30a and regulating Snail. J Cell Physiol. 2021; 236(1): 536-548.

68. Yuan, Y. Song, W. Pan, Y. Li, Y. Xu, M. Xie, et al. LncRNA SLC26A4-AS1 suppresses the MRN complex-mediated DNA repair signaling and thyroid cancer metastasis by destabilizing DDX5. Oncogene. 2020; 39(43): 6664-6676.

69. Lemos, A. Matos, L. Ferreira, E. Gimba. PCA3The long non-coding RNA : an update of its functions and clinical applications as a biomarker in prostate cancer. Oncotarget. 2019; 10(61): 6589-6603.

70. Yörüker, M. Keskin, C. Kulle, S. Holdenrieder, U. Gezer. Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer. Biomed Rep. 2018; 9(2): 181-186.

71. Liu, J. Feng, M. Sun, G. Yang, H. Yuan, Y. Wang, et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019; 454: 158-170.

72. Xu, G. Zhou, H. Wang, Y. Liu, B. Chen, W. Chen, et al. Circulating IncRNA SNHG11 as a novel biomarker for early diagnosis and prognosis of colorectal cancer. Int J Cancer. 2020; 146(10): 2901-2912.

73. Guo, X. Lv, Y. Ru, F. Zhou, N. Wang, H. Xi, et al. Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Biomarker for Early Detection and Monitoring Progression of Gastric Cancer: A Multiphase Study. JAMA Surg. 2020; 155(7): 572-579.

74. Cantile, M. Di Bonito, M. Cerrone, F. Collina, M. De Laurentiis, G. Botti. HOTAIRLong Non-Coding RNA in Breast Cancer Therapy. Cancers. 2020; 12(5).

75. Kim, H. Jun, E. Kim, J. Lee, H. Park, C. Ryu, et al. HOTAIRGenetic Variants of Associated With Colorectal Cancer Susceptibility and Mortality. Front Oncol. 2020; 10: 72.

76. Zheng, J. Li, C. Ma, X. Tang, Q. Tang, J. Wu, et al. Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer. J Cell Mol Med. 2020; 24(10): 5578-5592.

77. Zhang, W. Qiu, H. Zhu, H. Liu, J. Sun, Y. Chen, et al. HOTAIR contributes to the carcinogenesis of gastric cancer via modulating cellular and exosomal miRNAs level. Cell Death Dis. 2020; 11(9):780.
78. Liu, G. Liu, Y. Lu, Y. Shi. Long non-coding RNA HOTAIR promotes cell viability, migration and invasion in thyroid cancer cells by sponging miR-17-5p. Neoplasma. 2020; 67(2): 229-237.

79. Lu, P. Guo, A. Liu, I. Ares, M. Martínez-Larrañaga, X. Wang, et al. The role of long noncoding RNA in lipid, cholesterol, and glucose metabolism and treatment of obesity syndrome. Med Res Rev. 2020. Online ahead of print.

80. Cai, Y. Yang, X. Chen, G. Wu, X. Zhang, Y. Liu, J et al. Circulating 'IncRNA OTTHUMT00000387022' from monocytes as a novel biomarker for coronary artery disease. Cardiovasc Res. 2016; 112(3): 714-724.

81. Yang, Y. Cai, G. Wu, X. Chen, Y. Liu, X. Wang, et al. Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease. Clin Sci (Lond). 2015; 129(8): 675-685.

82. Kumarswamy, C. Bauters, I. Volkmann, F. Maury, J. Fetsch, A. Holzmann, et al. Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure. Circ Res. 2014; 114(10): 1569-1575.

83. Wang, L. Wang, Z. Ma, W. Liang, J. Li, Y. Li, et al. Early expressed circulating long noncoding RNA CHAST is associated with cardiac contractile function in patients with acute myocardial infarction. Int J Cardiol. 2020; 302: 15-20.

84. Vausort, D. Wagner, Y. Devaux. Long noncoding RNAs in patients with acute myocardial infarction. Circ Res. 2014; 115(7): 668-677.

85. Zheng, X. Liu, R. Han, W. Yuan, K. Sun, J. Zhong, et al. Circulating exosomal long non-coding RNAs in patients with acute myocardial infarction. J Cell Mol Med. 2020; 24(16): 9388-9396.

86. Wilusz, H. Sunwoo, D. Spector. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009; 23(13): 1494-14504.

87. Sánchez, M. Huarte. Long non-coding RNAs: challenges for diagnosis and therapies. Nucleic Acid Ther. 2013; 23(1): 15-20.

88. Kovacs, J. Shackelford, K. Tape, M. Richards, P. Faust, S. Fliesler, et al. Disturbed cholesterol homeostasis in a peroxisome-deficient PEX2 knockout mouse model. Mol Cell Biol. 2004; 24(1): 1-13.

89. Jiang, J. Tang, X. Xiao, W. Qi, S. Wu, C. Jiang, et al. Schnyder corneal dystrophy-associated UBIAD1 mutations cause corneal cholesterol accumulation by stabilizing HMG-CoA reductase. PLoS Genet. 2019; 15(7): e1008289.

90. Nowaczyk, M. Irons. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. Am J Med Genet C Semin Med Genet. 2012; 160C(4): 250-62.

91. Maranghi, G. Truglio, A. Gallo, E. Greico, A. Verrienti, A. Montali, et al. A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family. Biochem Biophys Res Commun. 2019; 508(2): 487-493.

92. Lee, L. Kinch, D. Borek, J. Wang, J. Wang, I. Urbatsch, et al. Crystal structure of the human sterol transporter ABCG5/ABCG8. Nature. 2016; 533(7604): 561-564.
93. Ş. Temel, M. Ergören. The association between the chromosome 9p21 CDKN2B-AS1 gene variants and the lipid metabolism: A pre-diagnostic biomarker for coronary artery disease. Anatol J Cardiol. 2019; 21(1): 31-38.

94. Zhao, X. Wu, S. Nie, X. Gao, J. Sun, K. Li, et al. CDKN2B-AS1 Association of rs1333049 with Brain Diseases: A Case-control Study and a Meta-analysis. Clin Psychopharmacol Neurosci. 2017; 15(1): 53-58.

95. Liang, T. Fan, L. Liu, L. Zhang. Knockdown of growth-arrest specific transcript 5 restores oxidized low-density lipoprotein-induced impaired autophagy flux via upregulating miR-26a in human endothelial cells. Eur J Pharmacol.2019; 843: 154-161.

96. Ye, C. Wang, D. Wang, H. Yuan. LncRBA GSA5, up-regulated by ox-LDL, aggravates inflammatory response and MMP expression in THP-1 macrophages by acting like a sponge for miR-221. Exp Cell Res. 2018; 369(2): 348-355.

97. Xu, L. Xiao, C. Kang, L. Ding, F. Guo, P. Li, et al. LncRNA AC096664.3/PPAR-γ/ABCG1-dependent signal transduction pathway contributes to the regulation of cholesterol homeostasis. J Cell Biochem. 2019; 120(8): 13775-13782.

98. Hu, J. Yang, X. Ma, Z. Chen, Y. Hu, J. Zhao, et al. A lincRNA-DYNLRB2-2/GPR119/GLP-1R/ABCA1-dependent signal transduction pathway is essential for the regulation of cholesterol homeostasis. J Lipid Res. 2014; 55(4): 681-697.

99. Li, S. Shen, S. Ding, L. Wang. LincRNA DYN-LRB2-2 upregulates cholesterol efflux by decreasing TLR2 expression in macrophages. J Cell Biochem. 2018; 119(2): 1911-1921.

100. Lan, L. Wu, N. Wu, Q. Chen, Y. Li, X. Du, et al. Long Noncoding RNA Inc-HC Regulates PPARγ-Mediated Hepatic Lipid Metabolism through miR-130b-3p. Mol Ther Nucleic Acids. 2019; 18: 954-965.

101. Lan, J. Yan, J. Ren, B. Zhong, J. Li, Y. Li, et al. A novel long noncoding RNA Lnc-HC binds hnRNPA2B1 to regulate expressions of Cyp7a1 and Abca1 in hepatocytic cholesterol metabolism. Hepatology. 2016; 64(1):58-72.

102. Liu, L. Tan, J. Yao, L. Yang. Long non-coding RNA MALAT1 regulates cholesterol accumulation in ox-LDL-induced macrophages via the microRNA-17-5p/ABCA1 axis. Mol Med Rep.2020; 21(4):1761-1770.

103. Yan, J. Chen, N. Chen. Long noncoding RNA MALAT1 promotes hepatic steatosis and insulin resistance by increasing nuclear SREBP-1c protein stability. Sci Rep. 2016; 6: 22640.

104. Zhen, S. Ren, H. Ji, X. Ding, P. Zou, J. Lu. The IncRNA DAPK-IT1 regulates cholesterol metabolism and inflammatory response in macrophages and promotes atherogenesis. Biochem Biophys Res Commun. 2019; 516(4):1234-1241.

105. Mohamadi, H. Ghaedi, F. Kazerouni, M. Erfanian Omidvar, S. Kalbasi, M. Shanaki, et al. Deregulation of long noncoding RNA SNHG17 and TTC28-AS1 is associated with type 2 diabetes mellitus. Scand J Clin Lab Invest. 2019; 79(7): 519-523.

106. Pang, J. Wang, P. Hu, J. Jiang, C. Yu. HOTAIR alleviates ox-LDL-induced inflammatory response in Raw264.7 cells via inhibiting NF-κB pathway. Eur Rev Med Pharmacol Sci. 2018; 22(20): 6991-6998.
107. Li, X. Yan, G. Xu, Z. Pang, J. Weng, J. Yin, et al. A novel plasma lncRNA ENST00000416361 is upregulated in coronary artery disease and is related to inflammation and lipid metabolism. Mol Med Rep. 2020; 21(6): 2375-2384.

108. Sun, Y. Song, C. Liu, J. Geng. LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling. Biochem Biophys Res Commun. 2019; 516(2): 584-590.

109. Zhang, J. Wu, C. Wu, W. Chen, R. Lin, Y. Zhou, et al. The LINC01138 interacts with PRMT5 to promote SREBP1-mediated lipid desaturation and cell growth in clear cell renal cell carcinoma. Biochem Biophys Res Commun. 2018; 507: 337-342.

110. Ray, A. Hansen, S. Slott, M. Taskova, K. Astakhova, K. Morris. Control of LDL Uptake in Human Cells by Targeting the LDLR Regulatory Long Non-coding RNA BM450697. Mol Ther Nucleic Acids. 2019; 17: 264-276.

111. Mitchell, E. Theusch, C. Cubitt, A. Dosé, K. Stevens, D. Naidoo, et al. RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol. Circulation. Circ Cardiovasc Genet. 2016; 9(3): 223-230.

112. Zhao, X. Xiong, T. Liu, L. Mi, X. Peng, C. Rui, et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nat Commun. 2018; 9(1): 2986.

113. Tang, R. Yin, H. Shi, X. Wang, D. Shen, X. Wang, et al. LncRNA ZFAS1 confers inflammatory responses and reduces cholesterol efflux in atherosclerosis through regulating miR-654-3p-ADAM10/RAB22A axis. Int J Cardiol. 2020; 315: 72-80.

114. Wang, D. Xiang, S. Mei, Y. Jin, D. Sun, C. Chen, et al. The novel long noncoding RNA Lnc19959.2 modulates triglyceride metabolism-associated genes through the interaction with Purb and hnRNPA2B1. Mol Metab. 2020; 37: 10096.

Tables

Table 1. Congenital diseases caused by aberrant cholesterol homeostasis.
| Congenital diseases          | Underlying mechanism                                                      | Featured symptoms                                                                 | Mutant genes | refs |
|------------------------------|---------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------|------|
| Zellweger syndrome           | Disturbed cholesterol homeostasis                                         | A lethal inherited disorder characterized by severe defects in peroxisome biogenesis and peroxisomal protein import | PEX2         | [88] |
| Schnyder corneal dystrophy   | Enhanced free cholesterol production because of stabilizing HMG-CoA reductase | Cholesterol accumulation in the cornea; corneal opacification                     | UBIAD1       | [89] |
| Smith-Lemli-Opitz syndrome   | 7-Dehydrocholesterol accumulation and cholesterol deficiency               | Mental and growth retardation; cleft palate; malformations of heart, kidney, and genitals (males); polydactyly or syndactyly | DHCR7        | [90] |
| Familial hypercholesterolemia| Impaired LDLR-mediated LDL uptake                                         | Markedly elevated plasma levels of cholesterol-containing LDLs; premature coronary heart disease | LDLR, APOB, PCSK9, | [7]  |
| Tangier disease              | Impaired ABCA1-mediated cholesterol efflux                                 | Extremely low HDL and apoA-1; massive deposition of cholesteryl esters in macrophage-rich tissues; increased risk of CAD | ABCA1        | [91] |
| Sitosterolemia               | Impaired ABCG5 and ABCG8-mediated cholesterol efflux                       | Elevated plasma and tissue levels of plant sterols and cholesterol; xanthomas; premature cardiovascular disease | ABCG5, ABCG8 | [92] |

APOB: apolipoprotein B, DHCR7: 7-dehydrocholesterol reductase, LDLR: low-density lipoprotein receptor, PCSK9: Proprotein convertase subtilisin/kexin type 9, PEX2: peroxisomal E3 ubiquitin ligase peroxin 2, UBIAD1: UbiA prenyltransferase domain-containing protein 1.

Table 2. Summary of IncRNAs diseases with disturbed cholesterol homeostasis.
| LncRNAs         | Target genes                  | Function                                         | Diseases and/or Treated                          | Refs |
|----------------|-------------------------------|-------------------------------------------------|------------------------------------------------|------|
| CDKN2B-AS1     | ADAM10, CDKN2B-AS1(rs49777574, rs1333040, rs1333049), C/EBPβ, CDKN2B, EZH2 and CTCF | Cholesterol efflux (+) Lipid metabolism (+) LDL-C (-), HDL-C (+), and TC (-) | Atherosclerosis Hyperlipidemia families CAD Hemorrhagic stroke, Cerebrovascular disease | [43, 93, 94] |
| GAS5           | ABCA1 and miR-135a            | RCT (-) and lipid accumulation (+) Lipid uptake (+) | Coronary heart disease ApoE null mice with atherosclerosis | [95, 96] |
| MIAT           | HIF1α, ALKBH1                 | Blood lipids levels (+), atherosclerotic plaques formation (+) | Patients with symptoms of vulnerable atherosclerotic plaque | [19] |
| CHROME         | LXR, ABCA1, miR-27b, miR-33a/b and miR-128 | Cholesterol efflux and HDL biogenesis (+) | Atherosclerotic vascular disease Human hepatocytes and macrophages | [29] |
| LINC00958      | HDGF,                         | Cellular cholesterol (+) and triglyceride levels (+) | HCC | [19] |
| ENST00000602558.1 | ABCG1, p65                 | Cholesterol efflux (+)                          | ac-LDL treated VSMCs; patients with CAD | [53] |
| AC096664.3     | PPAR-γ, ABCG1                | Cholesterol accumulation (-)                   | Atherosclerosis ox-LDL-treated VSMCs and THP-1 | [97] |
| DYNLRB2-2      | GPR119, GLP-1R, ABCA1, TLR2  | Cholesterol efflux (+) Lipid accumulation (-) | Atherosclerosis in apoE−/− mice ox-LDL-exposed THP-1 and RAW264.7 cells High-fat diet (HFD) apoE−/− mice | [98, 99] |
| H19            | PTBP1, miR-130b,             | Lipid                                           | Atherosclerosis | [20, |
| lncRNA | miRNA | Cholesterol Metabolism | Hepatic Lipogenesis | NAFLD | References |
|-------|-------|------------------------|---------------------|-------|------------|
| Lnc-HC | miR-130b-3p, PPARγ, CYP7A1 and ABCA1, hnRNPA2B1 | Lipid metabolism (+) | Hepatic lipogenesis (+) | NAFLD | [100, 101] |
| MEG3 | miR-21, LRP6, Nrf2, miR-136 | Lipid accumulation (+) | NAFLD | HFD-induced NAFLD mice model | [31, 33] |
| MALAT1 | ABCA1, miR-17-5p, SREBP-1c | Cholesterol efflux (+) | Hepatic steatosis and insulin resistance | ox-LDL-stimulated macrophages | [102, 103] |
| RP5-833A20.1 | miR-382-5p, NFIA | Cholesterol homeostasis (+) | Cardiovascular disease | ApoE−/−mice with atherosclerosis | [57] |
| HOXC-AS1 | HOXC6 | Cholesterol accumulation (-) | ox-LDL-treated THP-1 cells | | [46] |
| DAPK1-IT1 | miR-590-3p, LPL, ABCA1, ABCG1 CD36, NF-kB | Cholesterol metabolism (+) | HFD-induced apoE−/−mice, ox-LDL-treated ECs, SMCs, and THP-1 cells | | [104] |
| SNHG17 | - | HDL-C level (-) | Type 2 diabetes mellitus | | [105] |
| TTC28-AS1 | - | LDL-C level (+) | Type 2 diabetes mellitus | | [105] |
| HOTAIR | FXR1, NF-κB | Lipid accumulation (-) | Atherosclerosis | ox-LDL-treated Raw264.7 cells | [106] |
| LncRNA/Protein | Regulation | Function | Conditions/Model | References |
|---------------|------------|----------|------------------|------------|
| ENST00000416361 | SREBP1, SREBP2 | Lipid metabolism (+) | CAD | [107] |
| NEAT1 | SREBP1, AMPK | Lipid metabolism (+) | Nonalcoholic fatty liver disease | [108] |
| LINC01138 | PRMT5, SREBP1 | Lipid desaturation (+) | Kidney malignancy | [109] |
| BM450697 | LDLR | Regulates cholesterol in the blood | Atherosclerotic cardiovascular disease | [110] |
| RP1-13D10.2 | LDLR | LDL uptake (+) | Simvastatin and sham incubated lymphoblastoid cell lines from participants | [111] |
| Blnc1 | LXR-SREBP1c | Hepatic lipogenesis (+) | Nonalcoholic fatty liver disease and insulin resistance | [112] |
| LeXis | LXR, SREBP2 | Cholesterol biosynthesis (-) | Western diet-induced C57Bl/6 mice model | [34] |
| ZFAS1 | miR-654-3p, ADAM10, RAB22A | Cholesterol efflux (-) | ox-LDL treated THP-1 cells | [113] |
| Lnc19959.2 | hnRNPA2B1 | Triglyceride metabolism (+) | Rat liver with hypertriglyceridemia | [114] |

**Figures**
LncRNAs regulate cholesterol homeostasis in hepatocytes and macrophages. LncRNAs in the liver regulate cholesterol accumulation, cholesterol efflux, cholesterol biosynthesis, and cholesterol metabolism. LncRNAs control cholesterol accumulation and cholesterol efflux in atherosclerotic plaques. LncRNAs regulate ABCA1 expression and inhibit cholesterol efflux to lipid poor apoA-I, which initiates nascent high-density lipoproteins (HDLs). LncRNAs control SREBP1, ACC1, SCD1, FASN, CYP7A1, and ACSL1 expression in hepatocytes. Meantime, IncRNAs also regulate NFIA, ApoE, CDKN2B, RAB22A, CD36, ABCG1, and ADAM10 expression in the macrophages accumulated in atherosclerotic plaques. Free cholesterol in the nascent HDL is further esterified to cholesteryl ester by lecithin-cholesterol acyltransferase (LCAT), which results in the formation of mature HDL particles. Purple indicates IncRNAs. Black represents the target genes regulated by LncRNAs. Blue, inhibit; Red, promote.
The IncRNA-associated ceRNA networks affect the four common cholesterol transport models of liver diseases. Representative IncRNA-ceRNA networks are listed. They highlighted the involvement of IncRNA-ceRNA networks in four common cholesterol transport models of liver diseases: cholesterol accumulation, cholesterol efflux, cholesterol biosynthesis, and cholesterol metabolism. ACCα, Acetyl-CoA carboxylase α; CaM, calmodulin; FAS, fatty acid synthase; G6Pase, glucose-6-phosphatase; hnRNPA1, heterogeneous nuclear ribonucleoprotein A1; LncLSTR, liver-specific triglyceride regulator; LncSHGL, hepatic gluconeogenesis, and lipogenesis; Mirt2, long noncoding RNA myocardial infarction associated transcript 2; PEPCK, phosphoenolpyruvate carboxykinase.
Figure 3

The lncRNAs affect cholesterol accumulation and cholesterol efflux from THP-1 macrophage-derived foam cells in atherosclerotic disease. CTCF, CCCTC-binding factor; DNMT1, DNA methyltransferase 1; EZH2, enhancer of zeste homolog 2; HOXC-AS1, lncRNA HOXC cluster antisense RNA 1; Kcnq1ot1, Kcnq1 overlapping transcript 1; LncRNA MAARS, Macrophage-Associated Atherosclerosis lncRNA Sequence; NFIA, nuclear factor IA.